Antigen-Specific B-Cell Response to 13-Valent Pneumococcal Conjugate Vaccine in Asplenic Individuals With -Thalassemia Previously Immunized With 23-Valent Pneumococcal Polysaccharide Vaccine | Zendy

Ioanna Papadatou | Zendy; Christina Piperi | Zendy; Krystallenia Alexandraki | Zendy; Antonis Kattamis | Zendy; M. Theodoridou | Zendy; Vana Spoulou | Zendy

Open Access

Antigen-Specific B-Cell Response to 13-Valent Pneumococcal Conjugate Vaccine in Asplenic Individuals With -Thalassemia Previously Immunized With 23-Valent Pneumococcal Polysaccharide Vaccine

Author(s) -

Ioanna Papadatou,

Christina Piperi,

Krystallenia Alexandraki,

Antonis Kattamis,

M. Theodoridou,

Vana Spoulou

Publication year - 2014

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciu409

Subject(s) - medicine , pneumococcal conjugate vaccine , pneumococcal polysaccharide vaccine , immunology , pneumococcal vaccine , thalassemia , immune system , conjugate vaccine , pneumococcal infections , streptococcus pneumoniae , antigen , vaccination , virology , pneumococcal disease , immunogenicity , microbiology and biotechnology , biology , antibiotics

Current guidelines recommend a combined schedule of a 13-valent pneumococcal conjugate vaccine (PCV13) and PPSV23 (23-valent polysaccharide vaccine) for asplenic individuals. We show that PCV13 induces a T-dependent immune response in asplenic individuals with β-thalassemia, but previous PPSV23s affect the memory B-cell response in a dose- and time-dependent manner. Clinical Trials Registration. NCT01846923.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research